Role of Artesunate on cardiovascular complications in rats with type 1 diabetes mellitus

BackgroundThe present study aimed to evaluate the effect of artesunate (ART) on the reduction of cardiovascular complications in a type 1 diabetes model and to investigate the associated mechanism based on the receptor for advanced glycation end-product (RAGE)/NF-kappa B signaling pathway.MethodsA total of 40 male Sprague-Dawley rats were randomly divided into five groups: The healthy, diabetic, 50mg/kg ART (ig) treatment diabetic, 100mg/kg ART (ig) treatment diabetic, and 6U/kg insulin (iH) treatment diabetic groups. The treatment lasted 4weeks after the diabetic model was established via intraperitoneal injection of streptozotocin. Blood samples were collected, and cardiovascular tissues were harvested and processed to measure various parameters after the animals were sacrificed. The myocardium and aortic arch tissues were evaluated using hematoxylin-eosin and Masson staining. Expression levels of RAGE, NF-kappa B, matrix metalloproteinase MMP9, MMP1 and CD68 in the myocardium and aortic arch tissues were detected using immunohistochemistry, and mRNA expression was determined using reverse transcription-quantitative PCR.ResultsThe results of the present study demonstrated that ART treatment may restrain diabetes-induced cardiovascular complications by maintaining heart and body weight while reducing blood glucose, as well as regulating blood lipid indicators to normal level (P<0.05). The expression levels of NF-<kappa>B, CD68, MMP1, MMP9 and RAGE were decreased in the ART-treated diabetic rats (P<0.05).ConclusionsART treatment may have a protective role against diabetes-associated cardiovascular complications in diabetic rats by inhibiting the expression of proteins in the RAGE/NF-<kappa>B signaling pathway and downstream inflammatory factors. High concentrations of ART had a hypoglycemic effect, while a low concentration of ART prevented cardiovascular complications.